Michel Dahan, SVP, Chief Operating Officer at Akebia Therapeutics, Inc. (AKBA), sold 34,840 shares at $1.26 ($44K) on 2024-05-13, disclosed to the SEC on 2024-05-14.
Scheduled sale ($44k) by SVP, Chief Operating Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| AKBA | SELL | 2023-05-25 | $233K | — | Filing → |
| AKBA | SELL | 2023-03-03 | $18K | — | Filing → |
| AKBA | SELL | 2023-03-01 | $8K | — | Filing → |